Oriola Corp Class B · OMXHEX:ORIOLA
Oriola Corp Class B — Investor Presentation (November 2023)
14 slides from Oriola Corp Class B's investor presentation, November 2023
Slide 1: Oriola's way forward: The leading specialist in wholesale of pharmaceuticals and health products
Oriola’s way forward: The leading specialist in wholesale of pharmaceuticals and health products 1 November 2024
Slide 2: We create value through the entire healthcare value chain
We create value through the entire healthcare value chain Our purpose, ‘Health for life’, is the essence of what we stand for. Together with our employees, customers and partners, we are working towards our vision of enabling a healthier tomorrow. Our core business, pharmaceutical distribution and
Slide 3: Market drivers creating opportunities
Market drivers creating opportunities • Preventive care is growing as • In general, the products are people are willing to invest in suitable to sell and distribute their high quality and active via online channels. • The share of people older lifestyle. • Increased individual pharma • Digitalisatio
Slide 4: A stable and growing business environment
A stable and growing business environment • Growing pharmaceutical distribution market, approximately 6% growth rate in the past 4 years Public and private healthcare • Market size of EUR 8.5 billion, Finland and Sweden combined Pharmacies Veterinarians and clinics • Stable market in uncertain econo
Slide 5: Oriola's refined business strategy – the way forward
Oriola’s refined business strategy – the way forward 2024–2026 2023 The leading specialist The forerunner in in wholesale of the advanced pharmaceuticals and distribution of health products pharmaceuticals and in providing advisory services to pharmaceutical companies • Strong partnerships • Enhance
Slide 6: Our ambitious targets generate value
Our ambitious targets generate value Empowering Oriola: long-term financial targets Three long-term financial targets and dividend policy GROWTH PROFITABILITY EQUITY DIVIDEND POLICY Annual sales growth at Adjusted EBIT margin Return on equity >20% Oriola’s aim is to pay out an the rate of market, ab
Slide 7: Three strategic goals defining our future
Three strategic goals defining our future
Slide 8: Delivering customer value through integrated service offering
Pharma- ceutical companies Delivering customer value through Pharmacies integrated service offering Distribution Wholesale is our Advisory Public and Customer provides logistics and dose business in traded goods and OTC provides expert services to experience private healthcare dispensing offered to
Slide 9: A winning culture with a transformative business
A winning culture with a transformative business • Fulfilling customer expectations • Integrated customer offerings • Wholesale and Distribution • Infrastructure fit for purpose • Data and insight driven business and digital services • Collaborative and transparent culture • Sustainability in everyt
Slide 10: Our new sustainability agenda leads our continued actions towards a healthier tomorrow
Our new sustainability agenda leads our continued actions towards a healthier tomorrow 10
Slide 11: Sustainability goals
v \ SUSTAINABILITY Safeguarding GOALS deliveries for health and wellbeing Advancing a sustainable Pursuing people a net-zero journey impact on Ontine pharmaceuticals and digitalisation &, aa ee "eg ng, iS “oi
Slide 12: 12
12
Slide 13: New reporting segments as of 1 Jan 2024
New reporting segments as of 1 Jan 2024 Oriola is updating its segment reporting to reflect the new strategy and to improve transparency. Oriola’s two reporting segments as of 1 January 2024 will be: Preliminary, unaudited figures for 2022 Segment name Definition including dose dispensing business i
Slide 14: Outlook 2023
Outlook 2023 Oriola expects the adjusted EBIT, excluding the dose dispensing business in Sweden, for the year 2023 to be on the same level as adjusted EBIT for 2022 (EUR 19.7 million). Oriola’s adjusted EBIT, excluding the dose dispensing business in Sweden, for the year 2022 was EUR 11.9 million. T